These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. Gottlieb AB; Kircik L; Eisen D; Jackson JM; Boh EE; Strober BE; Frankel E; Xia HA; Stevens SR J Dermatolog Treat; 2006; 17(6):343-52. PubMed ID: 17853307 [TBL] [Abstract][Full Text] [Related]
24. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734 [TBL] [Abstract][Full Text] [Related]
25. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. Zhou H; Mayer PR; Wajdula J; Fatenejad S J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641 [TBL] [Abstract][Full Text] [Related]
26. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699 [TBL] [Abstract][Full Text] [Related]
27. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Davis JC; van der Heijde DM; Braun J; Dougados M; Cush J; Clegg D; Inman RD; Kivitz A; Zhou L; Solinger A; Tsuji W Ann Rheum Dis; 2005 Nov; 64(11):1557-62. PubMed ID: 15843448 [TBL] [Abstract][Full Text] [Related]
28. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Elkayam O; Caspi D; Reitblatt T; Charboneau D; Rubins JB Semin Arthritis Rheum; 2004 Feb; 33(4):283-8. PubMed ID: 14978666 [TBL] [Abstract][Full Text] [Related]
30. Etanercept: a new era in the treatment of psoriatic arthritis. Mease PJ Am J Manag Care; 2002 Apr; 8(6 Suppl):S181-93. PubMed ID: 11990863 [TBL] [Abstract][Full Text] [Related]
31. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. de Vlam K; Lories RJ Rheumatology (Oxford); 2006 Mar; 45(3):321-4. PubMed ID: 16234275 [TBL] [Abstract][Full Text] [Related]
32. Psoriatic arthritis patients doing better on infliximab than etanercept. Smith N; Gadsby K; Deighton C Rheumatology (Oxford); 2007 Apr; 46(4):721-2. PubMed ID: 17314216 [No Abstract] [Full Text] [Related]
33. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. Delaunay C; Farrenq V; Marini-Portugal A; Cohen JD; Chevalier X; Claudepierre P J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699 [TBL] [Abstract][Full Text] [Related]
34. Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. Stiehm ER; Roberts RL; Kaplan MS; Corren J; Jaracz E; Rico MJ J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 2):S206-13. PubMed ID: 16021176 [TBL] [Abstract][Full Text] [Related]
35. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life. De Felice C; Mazzotta A; Esposito M; Bianchi L; Chimenti S J Dermatolog Treat; 2006; 17(6):355-8. PubMed ID: 17853309 [TBL] [Abstract][Full Text] [Related]
36. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Bingham CO; Looney RJ; Deodhar A; Halsey N; Greenwald M; Codding C; Trzaskoma B; Martin F; Agarwal S; Kelman A Arthritis Rheum; 2010 Jan; 62(1):64-74. PubMed ID: 20039397 [TBL] [Abstract][Full Text] [Related]
37. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231 [TBL] [Abstract][Full Text] [Related]
38. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. van Riel PL; Freundlich B; MacPeek D; Pedersen R; Foehl JR; Singh A; Ann Rheum Dis; 2008 Aug; 67(8):1104-10. PubMed ID: 17666447 [TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Horneff G; De Bock F; Foeldvari I; Girschick HJ; Michels H; Moebius D; Schmeling H; Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440 [TBL] [Abstract][Full Text] [Related]
40. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Braun J; McHugh N; Singh A; Wajdula JS; Sato R Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]